These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15719353)

  • 1. Points to consider: the roles of surveillance and epidemiology in advancing drug safety.
    Edwards R; Faich G; Tilson H;
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):665-7. PubMed ID: 15719353
    [No Abstract]   [Full Text] [Related]  

  • 2. Signal detection in pharmacovigilance: empirical evaluation of data mining tools.
    Chan KA; Hauben M
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):597-9. PubMed ID: 16134080
    [No Abstract]   [Full Text] [Related]  

  • 3. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 4. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 5. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug safety special: chasing shadows.
    Frantz S
    Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
    [No Abstract]   [Full Text] [Related]  

  • 7. Accelerating statistical research in drug safety.
    Bilker W; Gogolak V; Goldsmith D; Hauben M; Herrera G; Hochberg A; Jolley S; Kulldorff M; Madigan D; Nelson R; Shapiro A; Shmueli G
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):687-8. PubMed ID: 16941519
    [No Abstract]   [Full Text] [Related]  

  • 8. [Pharmacoepidemiology].
    Hallas J; Sørensen HT
    Ugeskr Laeger; 2005 May; 167(20):2186-90. PubMed ID: 15987081
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pharmacovigilance: theoretical and practical aspects].
    Paoletti V; Galeotta G; Mammarella A
    Clin Ter; 1997 Mar; 148(3):67-73. PubMed ID: 9377842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 11. Active drug safety surveillance: a tool to improve public health.
    Platt R; Madre L; Reynolds R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance of adverse drug events in a large tertiary-care hospital.
    Nobre C; McKay C
    Conn Med; 2012 Feb; 76(2):91-4. PubMed ID: 22670359
    [No Abstract]   [Full Text] [Related]  

  • 13. Data incompatibility of adverse event reports electronically submitted to the AERS database.
    Glass LM
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):212-3. PubMed ID: 18236510
    [No Abstract]   [Full Text] [Related]  

  • 14. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 16. [Adverse drug effects. Prevention, detection and early intervention by a computer-assisted early warning system].
    Krebs S; Dormann H; Hahn EG; Schneider HT; Brune K
    Dtsch Med Wochenschr; 2000 Aug; 125(33):984-7. PubMed ID: 10994408
    [No Abstract]   [Full Text] [Related]  

  • 17. [The Medical Products Agency suggests improved drug safety follow-ups. New grasps of better knowledge and adverse effects reporting].
    Sjölin-Forsberg G; Lindeskog B; Lundqvist KM; Feltelius N; Alvan G
    Lakartidningen; 2007 Apr 18-24; 104(16):1226-9. PubMed ID: 17536352
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What evidence is required for drug exposure to be causally associated with adverse events? The case for case reports published in Pharmacotherapy.
    DeVane CL
    Pharmacotherapy; 2013 Feb; 33(2):115-7. PubMed ID: 23386592
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.